We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
PURPOSE This phase III trial aim ed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer ( NSCLC ) . PATIENTS AND METHODS Chemotherapy-naïve patients with stage III , stage IV , or recurrent NSCLC age ≥ 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were r and omly assigned to receive docetaxel 60 mg/m(2 ) on day 1 , every 3 weeks , or docetaxel 20 mg/m(2 ) plus cisplatin 25 mg/m(2 ) on days 1 , 8 , and 15 , every 4 weeks . The primary end point was overall survival ( OS ) . RESULTS In the first interim analysis , OS of the doublet arm was inferior to that of the monotherapy arm ( hazard ratio [ HR ] , 1.56 ; 95 % CI , 0.98 to 2.49 ) , and the predictive probability that the doublet arm would be statistically superior to the monotherapy arm on final analysis was 0.996 % , which led to early study termination . In total , 276 patients with a median age of 76 years ( range , 70 to 87 years ) were enrolled . At the up date d analysis , the median survival time was 14.8 months for the monotherapy arm and 13.3 months for the doublet arm ( HR , 1.18 ; 95 % CI , 0.83 to 1.69 ) . The rates of grade ≥ 3 neutropenia and febrile neutropenia were higher in the monotherapy arm , and those of anorexia and hyponatremia were higher in the doublet arm . CONCLUSION This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV